Pegylated granulocyte colony-stimulating factor conveys long-term neuroprotection and improves functional outcome in a model of Parkinson’s disease
Brain, 04/06/2012

Frank T et al. – The more stable levels of pegylated neuroprotective proteins in serum and cerebrospinal fluid may represent a general advantage in the treatment of chronic neurodegenerative diseases and the resulting longer injection intervals are likely to improve patient compliance. In summary, the authors found that pegylation of a neuroprotective growth factor improved its pharmacokinetic profile over its non–modified counterpart in an in vivo model of Parkinson’s disease.